* AVITA Medical Inc AVH.AX is expected to show a rise in
quarterly revenue when it reports results on May 13 for the
period ending March 31 2024
* The Valencia California California-based company is
expected to
report a 5.3% increase in revenue to $11.113 million from $10.55
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
* LSEG's mean analyst estimate for AVITA Medical Inc is for
a
loss of 47 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AVITA
Medical Inc
is A$4.75, above its last closing price of A$2.70.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.41 -0.38 -0.06 Beat 85.3
Sep. 30 2023 -0.44 -0.41 -0.07 Beat 83.5
Jan. 1 0001 -0.34 -0.34 -0.08 Beat 75.8
Jan. 1 0001 -0.32 -0.33 -0.07 Beat 77.3
Dec. -0.30
31 2022
Sep. 30 2022 -0.30
Jun. 30 2022 -0.32
Mar. 31 2022 -0.34
This summary was machine generated May 10 at 20:02 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)